{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-22-000105","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.575498+00:00","generated_at":"2026-06-24T05:47:46.925200+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veracyte Q2 revenue $72.9M (+32% YoY); net loss $9.5M, EPS -$0.13","bullets":["Revenue $72.9M, +32% YoY; testing $59.7M (+18%), biopharma $10.0M (vs $1.6M).","Test volume 24,904, +19% YoY; GAAP gross margin 59%, non-GAAP 66%.","Net loss $9.5M (+5% YoY), EPS -$0.13; non-GAAP op expenses $49.0M.","Cash and investments $164.0M at June 30; operating cash flow improved $29.4M YTD.","AUA/ASRO guideline now favorable for Decipher Prostate; multiple clinical data presentations at ASCO, ENDO, ESMO."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-22-000105","json":"https://secwatch.observer/filing/0001384101-22-000105.json","markdown":"https://secwatch.observer/filing/0001384101-22-000105.md","text":"https://secwatch.observer/filing/0001384101-22-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000105/0001384101-22-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000105/vcyt-20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:47:46.925200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}